FDA cuts deal with Neuromed over chronic pain drug

Canadian firm Neuromed Pharmaceuticals has concluded a special protocol assessment with the FDA for a Phase III clinical trial of its chronic pain treatment. The SPA is part of Neuromed's strategy to release its candidate, known as NMED-1077, in U.S. market by 2009 for people with conditions that result in acute, chronic pain.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY